Literature DB >> 26046131

Integrative genomic analyses of the RNA-binding protein, RNPC1, and its potential role in cancer prediction.

Zhiming Ding1, Hai-Wei Yang2, Tian-Song Xia3, Bo Wang4, Qiang Ding3.   

Abstract

The RNA binding motif protein 38 (RBM38, also known as RNPC1) plays a pivotal role in regulating a wide range of biological processes, from cell proliferation and cell cycle arrest to cell myogenic differentiation. It was originally recognized as an oncogene, and was frequently found to be amplified in prostate, ovarian and colorectal cancer, chronic lymphocytic leukemia, colon carcinoma, esophageal cancer, dog lymphomas and breast cancer. In the present study, the complete RNPC1 gene was identified in a number of vertebrate genomes, suggesting that RNPC1 exists in all types of vertebrates, including fish, amphibians, birds and mammals. In the different genomes, the gene had a similar 4 exon/3 intron organization, and all the genetic loci were syntenically conserved. The phylogenetic tree demonstrated that the RNPC1 gene from the mammalian, bird, reptile and teleost lineage formed a species-specific cluster. A total of 34 functionally relevant single nucleotide polymorphisms (SNPs), including 14 SNPs causing missense mutations, 8 exonic splicing enhancer SNPs and 12 SNPs causing nonsense mutations, were identified in the human RNPC1 gene. RNPC1 was found to be expressed in bladder, blood, brain, breast, colorectal, eye, head and neck, lung, ovarian, skin and soft tissue cancer. In 14 of the 94 tests, an association between RNPC1 gene expression and cancer prognosis was observed. We found that the association between the expression of RNPC1 and prognosis varied in different types of cancer, and even in the same type of cancer from the different databases used. This suggests that the function of RNPC1 in these tumors may be multidimensional. The sex determining region Y (SRY)-box 5 (Sox5), runt-related transcription factor 3 (RUNX3), CCAAT displacement protein 1 (CUTL1), v-rel avian reticuloendotheliosis viral oncogene homolog (Rel)A, peroxisome proliferator-activated receptor γ isoform 2 (PPARγ2) and activating transcription factor 6 (ATF6) regulatory transcription factor binding sites were identified in the upstream (promoter) region of the RNPC1 gene, and may thus be involved in the effects of RNPC1 in tumors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26046131     DOI: 10.3892/ijmm.2015.2237

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

Review 1.  RBM38 in cancer: role and mechanism.

Authors:  Cheng Zou; Ying Wan; Lingjing He; Jin Hai Zheng; Yang Mei; Junfeng Shi; Min Zhang; Zhiqiang Dong; Dingxiao Zhang
Journal:  Cell Mol Life Sci       Date:  2020-07-08       Impact factor: 9.261

2.  RBP-TSTL is a two-stage transfer learning framework for genome-scale prediction of RNA-binding proteins.

Authors:  Xinxin Peng; Xiaoyu Wang; Yuming Guo; Zongyuan Ge; Fuyi Li; Xin Gao; Jiangning Song
Journal:  Brief Bioinform       Date:  2022-07-18       Impact factor: 13.994

3.  In silico epitope prediction, expression and functional analysis of Per a 10 allergen from the American cockroach.

Authors:  Xunliang Tong; Miao Guo; Min Jin; Hao Chen; Yanming Li; Ji-Fu Wei
Journal:  Int J Mol Med       Date:  2016-10-26       Impact factor: 4.101

4.  Molecular cloning, expression, IgE binding activities and in silico epitope prediction of Per a 9 allergens of the American cockroach.

Authors:  Haiwei Yang; Hao Chen; Min Jin; Hua Xie; Shaoheng He; Ji-Fu Wei
Journal:  Int J Mol Med       Date:  2016-10-27       Impact factor: 4.101

Review 5.  RBM22, a Key Player of Pre-mRNA Splicing and Gene Expression Regulation, Is Altered in Cancer.

Authors:  Benoît Soubise; Yan Jiang; Nathalie Douet-Guilbert; Marie-Bérengère Troadec
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

Review 6.  Research progress on RNA-binding proteins in breast cancer.

Authors:  Ying Chen; Hai Qin; Lufeng Zheng
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.